IP Strategies for the New Political and Legislative Landscape

The Brexit vote added further uncertainty to an already precarious life sciences IP market. And, with the Unified Patent Court now thrown into confusion, the political and legislative landscape is one to navigate with caution.

Against this backdrop, the second annual Pharma and Biotech IP Summit will once again bring together leading IP experts from across life sciences. Attendees will hear the latest IP strategies for thriving at a time when regulatory and legislative changes are significantly impacting business models.

How will you benefit from attending Pharma and Biotech IP Summit 2018?

• Understand how Galapagos and Basilea Phamaceutica are building IP strategies to prosper and thrive in the new political and legislative climate
• Hear the distinct patent eligibility approaches emerging in the United States, Europe and China from Teva Pharmaceuticals and Astex Pharmaceuticals
• Gain clarity from Mylan and Powell Gilbert LLP on the future of patent litigation in Europe and the unique challenges posed by the Unified Patent Court and Brexit

• Review the developments being made with second medical use patents with Novartis and the impact of changes to incentivisation and reimbursement

• Assess the latest Supplementary Protection Certificate updates with Astrazeneca and Mereo Biopharma and how IP strategies will need to adapt

Plus meet with senior decision makers and experts from across the industry during four hours of dedicated networking opportunities.